Cardio Diagnostics Holdings (NASDAQ: CDIO) CEO and Co-Founder Dr. Meesha Dogan appeared on the latest episode of The BioMedWire Podcast to discuss the company's mission to improve cardiovascular disease prevention and early detection through precision medicine. During the interview, Dogan highlighted the company's use of epigenetics, genetics, and artificial intelligence to develop clinical tests that make cardiovascular care more accessible and personalized.
A key focus of the discussion was Cardio Diagnostics' expansion into India through partnerships with Aimil Ltd. and Dr. Lal PathLabs. These collaborations aim to bring the company's AI-driven cardiovascular tests to one of the world's most populous countries, where heart disease is a leading cause of death. The move aligns with Cardio Diagnostics' strategy to broaden its global footprint and address unmet needs in cardiovascular health.
Dogan also provided an update on the company's progress through the Medicare reimbursement process. She noted that CPT coding and payment steps have been completed, while coverage determination remains underway. This milestone is crucial for making the company's tests accessible to a larger patient population and could significantly impact revenue streams if approved.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that leverages a proprietary Integrated Genetic-Epigenetic Engine, or Core Technology, for cardiovascular disease detection and management. The company aims to become a leading medical technology firm by improving prevention, detection, and treatment of cardiovascular conditions.
The full press release is available at https://ibn.fm/0VjIz. Further information about Cardio Diagnostics, including the latest news and updates, can be found in the company's newsroom at https://ibn.fm/CDIO.
This expansion and reimbursement progress underscore Cardio Diagnostics' commitment to making its innovative cardiovascular tests widely available. If successful, the company could disrupt traditional approaches to heart disease management by providing earlier, more precise detection. For investors and patients, the developments signal potential growth and improved health outcomes, though final coverage decisions remain pending.
